Tricia J. Vos

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index985citations35works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ubiquitin and proteasome pathways(22), Lymphoma Diagnosis and Treatment(17), Chronic Lymphocytic Leukemia Research(13), Microtubule and mitosis dynamics(6), Cancer-related Molecular Pathways(5)

Publications35 total

Supplementary Figure 3 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Table 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 4 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure Legend from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Table 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 3 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 2 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Table 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Data from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure Legend from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Table 1 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Data from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
Supplementary Figure 4 from MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
2023Open Access
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
ACS Medicinal Chemistry Letters·2015· 108 citedOpen Access
Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines
PLoS ONE·2014· 59 citedOpen Access
MLN0905, a Small-Molecule <i>PLK1</i> Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
Molecular Cancer Therapeutics·2012· 21 cited
Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)
Journal of Medicinal Chemistry·2011· 54 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Bradley Stringer(21), Kerri Lasky(21), Marc L. Hyer(21), Mark Manfredi(20), Debra Liao(20), Mark G. Qian(20), Ray Liu(19), Youlan Rao(19), Michelle Tighe Nestor(18), Matt O. Duffey(18), Judy Quiju Shi(17), Benjamin Amidon(17), Natalie D' Amore(17), Vaishali Shinde(16), Denise Driscoll(16), Suresh K. Balani(5), Stephen G. Stroud(5), Christopher F. Claiborne(5), Ryan Chau(5), Matthew O. Duffey(5)